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The age-and gender-adjusted incidence of cardiovascular
disease is higher in HIV-infected populations than in the
general population. This talk will discuss the possible rea-
sons for this excess risk, and suggest rational approaches
of how best to reduce it. Risk factors for cardiovascular
disease in HIV-infected persons can be broadly separated
into: (1) those affecting risk in the general population
(age, gender, smoking, diabetes, hypertension, dyslipidae-
mia); (2) those caused by the underlying HIV infection
and the associated immunodeficiency (interruption of
antiretroviral therapy activates coagulation and inflam-
matory pathways); and (3) those caused by the use of ART
(either directly or indirectly by affecting e.g. lipid levels).
The traditional risk factors (category 1) appear to affect
cardiovascular risk to a similar extent in HIV-infected pop-
ulations as they affect the risk in the general population;
however, the prevalence is higher in HIV-infected popula-
tions predominantly because of differences in life-style
behaviours, but ART also contributes. There are emerging
signals that some antiretroviral drugs may adversely affect
cardiovascular outcomes; such signals are currently under
investigation. Other drugs may increase 'beneficial' HDL-
cholesterol, although it remains to be determined
whether this affects cardiovascular outcomes. On balance,
the existing knowledge suggests that all three categories
contribute to cardiovascular risk in HIV-infected popula-
tions. No evidence-based interventions to curtail the risk
of cardiovascular disease risk in HIV-infected populations
exist. The best recommendation is currently to extrapolate
knowledge from the general population in managing
modifiable traditional risk factors. Also, it is recom-
mended not to interrupt antiretroviral therapy once initi-
ated, and to consider modifying the composition of the
antiretroviral regimen if components hereof are believed
to contribute to elevated cardiovascular disease per se or
to elevation of LDL-lipid fractions. The benefit:risk ratio
for the various medical interventions are most striking in
patients at elevated underlying risk of cardiovascular dis-
ease, and stratification of populations according to their
underlying risk hence required http://www.cphiv.dk/
TOOLS.aspx. ART should be initiated in asymptomatic
antiretroviral naïve patients with CD4 counts <350 cells/
μL. A randomised trial is currently being initiated to
address whether earlier initiation of ART – in the course of
the chronic HIV-infection – may reduce the risk of serious
non-AIDS events including cardiovascular disease. Until
this trial has been completed, there remains uncertainty
whether earlier use of ART than what is currently recom-
mended is beneficial.
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